<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; DIPP</title>
	<atom:link href="http://www.tapanray.in/tag/dipp/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting ‘The Moment of Truth’ on ‘Working of Patents’ in India</title>
		<link>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-moment-of-truth-on-working-of-patents-in-india</link>
		<comments>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/#comments</comments>
		<pubDate>Mon, 03 Nov 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[Indacaterol]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Onbrez]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Section 66]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[truth]]></category>
		<category><![CDATA[Unibrez Rotacaps]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6148</guid>
		<description><![CDATA[By a letter dated October 21, 2014 addressed to the Secretary, Department of Industrial Policy and Promotion (DIPP) of India, the domestic pharma major Cipla has sought for the revocation of five patents of Novartis AG’s respiratory drug Indacaterol (Onbrez) in India, &#8230; <a href="http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unilateral American Action on Agreed Bilateral Issues: Would India Remain Unfazed?</title>
		<link>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed</link>
		<comments>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/#comments</comments>
		<pubDate>Mon, 20 Oct 2014 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bilateral]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[cold]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[doctors without borders]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[feet]]></category>
		<category><![CDATA[healthBig]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[President Obama]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[sprycel]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Unfazed]]></category>
		<category><![CDATA[Unilateral]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6128</guid>
		<description><![CDATA[I discussed in one of my earlier blog posts titled “Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?” of October 6, 2014 that on April 30, 2014, the United States in its report on annual review &#8230; <a href="http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Discretionary ‘Non-Compete Clause’ in Pharma FDI: An Intriguing Decision</title>
		<link>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision</link>
		<comments>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/#comments</comments>
		<pubDate>Fri, 10 Jan 2014 07:05:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[clause]]></category>
		<category><![CDATA[compete]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[discretionary]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Note]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Press]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TWN]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4848</guid>
		<description><![CDATA[As I had commented before, the MNC investors, while acquiring controlling stake in the Indian pharmaceutical companies, henceforth, would not be generally allowed to include any ‘non-compete clause’ in their agreement with the Indian promoters. However, this clause may be &#8230; <a href="http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?</title>
		<link>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes</link>
		<comments>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/#comments</comments>
		<pubDate>Mon, 18 Nov 2013 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[asset]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ilk]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Opinionated]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shorn]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[wage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4217</guid>
		<description><![CDATA[In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&#38;D, new job creation and ultimately to help aligning Indian &#8230; <a href="http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Ghost Keeps Haunting: NCD Dogs Cancer in &#8216;Compulsory License&#8217; Debate of India</title>
		<link>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india</link>
		<comments>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/#comments</comments>
		<pubDate>Mon, 11 Mar 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Citizens']]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[collective]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[dogs]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[ghost]]></category>
		<category><![CDATA[haunting]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[keeps]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[protein]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treat]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[used]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2037</guid>
		<description><![CDATA[In November 2012, as a part of the ‘Campaign for Affordable Trastuzumab’ for the treatment of breast cancer, a citizens’ collective, reportedly sent an ‘Open Letter’ signed by around 200 cancer survivors, women’s groups, human rights and health rights campaigns &#8230; <a href="http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
